Biotech investors live and die by the binary news events generated by the drugmakers they invest in. Heron Therapeutics (NASDAQ: HRTX), for instance, is awaiting a decision from the Food and Drug Administration about its candidate HTX-011 for use in post-operative pain. Likewise, Alkermes (NASDAQ: ALKS) expects an FDA decision on its schizophrenia and bipolar treatment ALKS3831 on or before June 1.
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting